NovoCure Limited
14.68USD
-0.4200 (-2.78%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on NVCR.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 537.8M | 509.3M | 605.2M | 655.4M | 726.1M | 804.8M |
| Q1 | 137.5M | 122.2M | 138.5M | 155.0M | 174.1M | — |
| Q2 | 140.9M | 126.1M | 150.4M | 158.8M | 183.6M | — |
| Q3 | 131.0M | 127.3M | 155.1M | 167.2M | 182.2M | — |
| Q4 | 128.4M | 133.8M* | 161.3M* | 174.4M* | 185.7M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.880 | -1.95 | -1.56 | -1.22 | -1.24 | -.806 |
| Q1 | -.040 | -.500 | -.360 | -.310 | -.620 | — |
| Q2 | -.230 | -.540 | -.310 | -.360 | -.130 | — |
| Q3 | -.250 | -.460 | -.280 | -.330 | -.235 | — |
| Q4 | -.360 |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.443* |
| -.611* |
| -.220* |
| -.241 |
| — |
Debt level and coverage